WallStreetZenWallStreetZen

NASDAQ: YMAB
Y Mabs Therapeutics Inc Stock

$8.70-0.30 (-3.33%)
Updated May 26, 2023
YMAB Price
$8.70
Fair Value Price
$11.42
Market Cap
$380.00M
52 Week Low
$2.70
52 Week High
$20.48
P/E
-5.12x
P/B
3.52x
P/S
2.92x
PEG
N/A
Dividend Yield
N/A
Revenue
$75.03M
Earnings
-$73.89M
Gross Margin
89.6%
Operating Margin
-99.45%
Profit Margin
-98.5%
Debt to Equity
0.28
Operating Cash Flow
-$64M
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

YMAB Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how YMAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

YMAB ($8.70) is undervalued by 23.82% relative to our estimate of its Fair Value price of $11.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
YMAB ($8.70) is significantly undervalued by 23.82% relative to our estimate of its Fair Value price of $11.42 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
YMAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more YMAB due diligence checks available for Premium users.

Be the first to know about important YMAB news, forecast changes, insider trades & much more!

YMAB News

Valuation

YMAB fair value

Fair Value of YMAB stock based on Discounted Cash Flow (DCF)
Price
$8.70
Fair Value
$11.42
Undervalued by
23.82%
YMAB ($8.70) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
YMAB ($8.70) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
YMAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

YMAB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.12x
Industry
11.86x
Market
54.23x

YMAB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.52x
Industry
5.18x
YMAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

YMAB's financial health

Profit margin

Revenue
$20.3M
Net Income
-$6.4M
Profit Margin
-31.6%
YMAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
YMAB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$137.4M
Liabilities
$29.6M
Debt to equity
0.28
YMAB's short-term assets ($124.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YMAB's short-term assets ($124.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YMAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.1M
Investing
$0.0
Financing
$0.0
YMAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

YMAB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
YMAB$380.00M-3.33%-5.12x3.52x
BLUE$378.83M+2.30%-2.27x1.07x
OTLK$378.58M+9.26%-5.90x36.10x
SCPH$378.08M+2.92%-8.07x4.99x
HUMA$382.32M+2.49%-12.76x4.67x

Y Mabs Therapeutics Stock FAQ

What is Y Mabs Therapeutics's quote symbol?

(NASDAQ: YMAB) Y Mabs Therapeutics trades on the NASDAQ under the ticker symbol YMAB. Y Mabs Therapeutics stock quotes can also be displayed as NASDAQ: YMAB.

If you're new to stock investing, here's how to buy Y Mabs Therapeutics stock.

What is the 52 week high and low for Y Mabs Therapeutics (NASDAQ: YMAB)?

(NASDAQ: YMAB) Y Mabs Therapeutics's 52-week high was $20.48, and its 52-week low was $2.70. It is currently -57.52% from its 52-week high and 222.22% from its 52-week low.

How much is Y Mabs Therapeutics stock worth today?

(NASDAQ: YMAB) Y Mabs Therapeutics currently has 43,677,767 outstanding shares. With Y Mabs Therapeutics stock trading at $8.70 per share, the total value of Y Mabs Therapeutics stock (market capitalization) is $380.00M.

Y Mabs Therapeutics stock was originally listed at a price of $24.00 in Sep 21, 2018. If you had invested in Y Mabs Therapeutics stock at $24.00, your return over the last 4 years would have been -63.75%, for an annualized return of -22.41% (not including any dividends or dividend reinvestments).

How much is Y Mabs Therapeutics's stock price per share?

(NASDAQ: YMAB) Y Mabs Therapeutics stock price per share is $8.70 today (as of May 26, 2023).

What is Y Mabs Therapeutics's Market Cap?

(NASDAQ: YMAB) Y Mabs Therapeutics's market cap is $380.00M, as of May 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Y Mabs Therapeutics's market cap is calculated by multiplying YMAB's current stock price of $8.70 by YMAB's total outstanding shares of 43,677,767.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.